This notion in combination with our findings implies that the Polk status provides a novel parameter in predicting a tumor-specific hyper-responsiveness to cisplatin and screening of the Polk status in cancers likely provides an attractive avenue for personalized cancer medicine. This evidence concerns the gene POLK and cancer.